Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) - Pipeline Review, H2 2018
Summary
According to the recently published report 'Glutamate Carboxypeptidase 2 - Pipeline Review, H2 2018'; Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) pipeline Target constitutes close to 7 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.
Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) - Glutamate carboxypeptidase II (GCPII) is a membrane-bound binuclear zinc metallopeptidase with the highly expressed in nervous and prostatic tissue. Glutamate carboxypeptidase II (GCPII) is an enzyme encoded by the FOLH1 (folate hydrolase 1) gene. GCPII is intimately involved in the neuron-neuron and neuron-glia signaling via the hydrolysis of N-acetylaspartylglutamate (NAAG). The inhibition of the GCPII-controlled NAAG catabolism has been shown to plat important role in traumatic brain injury, stroke, neuropathic and inflammatory pain, amyotrophic lateral sclerosis, schizophrenia and prostate carcinoma.
The report 'Glutamate Carboxypeptidase 2 - Pipeline Review, H2 2018' outlays comprehensive information on the Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 1 and 2 respectively.
Similarly, the universities portfolio in Phase I stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology and Central Nervous System which include indications Prostate Cancer, Glioblastoma Multiforme (GBM), Metastatic Transitional (Urothelial) Tract Cancer, Neuropathic Pain (Neuralgia) and Renal Cell Carcinoma.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21)
- The report reviews Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) targeted therapeutics and enlists all their major and minor projects
- The report assesses Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) targeted therapeutics
Reasons to buy- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Introduction
- Global Markets Direct Report Coverage
- Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) - Overview
- Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) - Companies Involved in Therapeutics Development
- Crescendo Biologics Ltd
- Eisai Co Ltd
- Inovio Pharmaceuticals Inc
- Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) - Drug Profiles
- CB-307 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- E-2072 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- INO-5150 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- INO-5401 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Vaccine to Target Prostate Specific Membrane Antigen for Renal Cell Carcinoma - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Vaccine to Target PSMA and TARP for Prostate Cancer - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Vaccine to Target PSMA, STEAP1 and PAP for Prostate Cancer - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) - Dormant Products
- Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) - Discontinued Products
- Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) - Product Development Milestones
- Featured News & Press Releases
- Jun 21, 2018: Inovio Announces Treatment of First Patient in Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combination with Regeneron’s PD-1 Inhibitor
- May 17, 2018: Inovio Pharmaceuticals Demonstrates PSA Stabilizing Effect of INO-5150 Immunotherapy in Phase 1b Study for Prostate Cancer
- Nov 27, 2017: Inovio Pharmaceuticals SynCon TERT Cancer Immunotherapy Combined with Checkpoint Inhibitor Synergistically Shrinks Tumor and Improves Survival in Preclinical Tumor Model
- Nov 01, 2017: Inovio Pharmaceuticals Initiates Immuno-Oncology Clinical Study for Glioblastoma in Combination with Regenerons PD-1 Inhibitor
- Sep 11, 2017: Inovios Cancer Immunotherapy (INO-5150) Slowed PSA Rise and Significantly Increased PSA Doubling Times In Patients with Recurrent Prostate Cancer
- Jul 27, 2015: Inovio Pharmaceuticals Initiates Clinical Trial of INO-5150 DNA Immunotherapy for Prostate Cancer
- Feb 02, 2011: Inovio's Dual-Antigen SynCon DNA Vaccine For Prostate Cancer Induces Robust Responses In Preclinical Trial
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development by Stage of Development, H2 2018
- Number of Products under Development by Therapy Areas, H2 2018
- Number of Products under Development by Indication, H2 2018
- Number of Products under Development by Companies, H2 2018
- Products under Development by Companies, H2 2018
- Number of Products under Investigation by Universities/Institutes, H2 2018
- Products under Investigation by Universities/Institutes, H2 2018
- Number of Products by Stage and Mechanism of Actions, H2 2018
- Number of Products by Stage and Route of Administration, H2 2018
- Number of Products by Stage and Molecule Type, H2 2018
- Pipeline by Crescendo Biologics Ltd, H2 2018
- Pipeline by Eisai Co Ltd, H2 2018
- Pipeline by Inovio Pharmaceuticals Inc, H2 2018
- Dormant Products, H2 2018
- Dormant Products, H2 2018 (Contd..1), H2 2018
- Discontinued Products, H2 2018
- List of Figures
- Number of Products under Development by Stage of Development, H2 2018
- Number of Products under Development by Therapy Areas, H2 2018
- Number of Products under Development by Top 10 Indications, H2 2018
- Number of Products by Routes of Administration, H2 2018
- Number of Products by Stage and Routes of Administration, H2 2018
- Number of Products by Molecule Types, H2 2018
- Number of Products by Stage and Molecule Types, H2 2018